


# PRODUCT INFORMATION



## SRT 1720

Item No. 42531

**CAS Registry No.:** 925434-55-5  
**Formal Name:** N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide  
**Synonyms:** CAY10559, SIRT 1933  
**MF:** C<sub>25</sub>H<sub>23</sub>N<sub>7</sub>O<sub>5</sub>  
**FW:** 469.6  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

SRT 1720 is supplied as a crystalline solid. A stock solution may be made by dissolving the SRT 1720 in the solvent of choice, which should be purged with an inert gas. SRT 1720 is sparingly soluble (1-10 mg/ml) in acetonitrile:water (1:1).

### Description

SRT 1720 is a sirtuin 1 (SIRT1) activator ( $EC_{1.5} = 0.16 \mu\text{M}$  in a cell-free fluorescence polarization assay).<sup>1</sup> It reduces acetylated p53 levels in U2OS cells when used at a concentration of 0.1  $\mu\text{M}$ . Oral administration of SRT 1720 (100 mg/kg) reduces fed blood glucose levels, improves insulin sensitivity, and increases mitochondrial capacity in a diet-induced obese (DIO) mouse model of diabetes. It also improves liver, adipose tissue, and skeletal muscle insulin sensitivity in Zucker *fa/fa* genetically obese rats. SRT 1720 (25 mg/kg) decreases synovitis and delays the progression of surgically induced osteoarthritis in mice.<sup>2</sup>

### References

1. Milne, J.C., Lambert, P.D., Schenk, S., *et al.* Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature* **450(7170)**, 712-716 (2007).
2. Nishida, K., Matsushita, T., Takayama, K., *et al.* Intraperitoneal injection of the SIRT1 activator SRT1720 attenuates the progression of experimental osteoarthritis in mice. *Bone Joint Res.* **7(3)**, 252-262 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/16/2026

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM